Physician VC Dr. John Dayton on What It Takes to Actually Build a Winning Healthcare Startup

Key Podcast Moments

• Dr. John Dayton reveals the data behind his investment thesis: more than a quarter of billion-dollar healthcare companies built in the last decade had at least one clinician co-founder
• The Seven Ps framework for evaluating whether a health tech company is actually ready to be funded
• Why claiming to be the only company in a space is the fastest way to lose credibility with an investor
• What practicing emergency medicine on the Navajo Reservation during peak COVID taught John about building scalable solutions
• What winning actually looks like for Wildfire Partners and why it goes well beyond financial returns

The idea that doctors make poor entrepreneurs is one of medicine's most persistent myths. Dr. John Dayton has spent the better part of a decade quietly dismantling it. An emergency physician, Stanford innovation fellow, and co-founder of Wildfire Partners, John built his healthcare seed fund around a finding from a paper he co-authored: more than a quarter of healthcare companies that crossed the billion-dollar valuation mark in the last decade had at least one clinician co-founder. That number is not a footnote. It is the entire thesis.

In this episode of How I Doctor, John sits down with Dr. Graham Walker to explain what it actually takes to build a health tech company worth funding, and why physicians are better positioned to do it than most of the industry assumes.

John' has created the Seven Ps framework, a mnemonic he developed specifically for evaluating healthcare startups, where standard venture criteria fall short. The framework gives physician-founders and investors alike a structured way to assess whether a company is genuinely ready to scale or just a promising idea looking for capital. The Seven Ps are:

• Product: Is there a clear market solution with a large enough need?
• Property: Does the company have intellectual property that creates a defensible moat?
• Product Clearance: What is the regulatory strategy, and is there enough runway to fund it?
• Payment: Who are the early customers, what are they paying, and can it scale?
• Pilots: Is there real evidence the product works in clinical settings and that physicians are actually using it?
• Physician and Patient Feedback: Do clinicians, nurses, and staff want to use it?
• Publications: Is the company speaking the language of evidence-based medicine?

John is direct about what kills a pitch. Founders who claim to have no competitors signal immediately that they have not done their research. Projections that skip over the cost and timeline of FDA clearance suggest a founder who does not understand the terrain. What John wants to see instead is grounded confidence: a founder who can name their risks, explain their regulatory pathway, and point to a physician or health system that has already said they would buy the product if it existed.

The conversation also covers how AI is reshaping the economics of starting a health tech company. John reflects on a medical education company he built in the mid-2010s where the majority of the first year and most of the budget went to finding a reliable developer. That same product, he says, could likely be built in a weekend with today's tools. The lower barrier to entry is good news for physician-founders with strong clinical insight and limited technical background. But John is quick to note the tradeoff: when everyone can build, standing out requires something harder to replicate. Proprietary data, deep clinical relationships, proven pilots, and a clear regulatory strategy matter more now, not less. The opportunity is real, but the moat has to be real too.

Sevaro is a physician-led telestroke and neurology company that delivers rapid virtual neuro coverage that’s reliable. Learn more at https://sevaro.com/

Evidently - Leading AI-powered clinical data intelligence https://evidently.com/

Top Takeaways

Physician-founders who want to move from insight to investment need more than a good idea. This conversation revealed a set of principles that separate the companies that survive contact with a real health system from the ones that stall before they get there.